2. Search Result
Search Result
Results for "

positron emission tomography (PET)

" in MedChemExpress (MCE) Product Catalog:

60

Inhibitors & Agonists

1

Fluorescent Dye

1

Biochemical Assay Reagents

6

Peptides

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W100209
    5Me3F4AP

    		Potassium Channel Neurological Disease
    5Me3F4AP is a potent blocker of potassium channel, with the IC50 of 220 μM to 693 μM when the pH is increased from 6.4 to 9.1. 5Me3F4AP has the potential to cross the blood-brain barrier and potential application in positron emission tomography (PET) .
    5Me3F4AP
  • HY-101184
    T807
    2 Publications Verification

    AV-1451

    		 Tau Protein Neurological Disease
    T807 a novel tau positron emission tomography (PET) tracer.
    T807
  • HY-136873
    UCB-J

    		Synaptic Vesicle Proteins Others
    UCB-J is a positron emission tomography (PET) radioligand for the synaptic vesicle protein 2A (SV2A) .
    UCB-J
  • HY-128890B
    DOTA-​NHS-ester TFA
    1 Publications Verification

    		 ADC Linker Biochemical Assay Reagents Cancer
    DOTA-​NHS-ester (TFA) is used as a linker for affibody molecules, and it can be employed in small animal positron emission tomography (PET), single photon emission computed tomography (SPECT), and CT scanning. DOTA-​NHS-ester can be used to label radiotracers or imaging probes for tumor detection .
    DOTA-​NHS-ester TFA
  • HY-147173
    FAPI-74

    		FAP Cancer
    FAPI-74 is a PET (positron emission tomography) tracer targeting the fibroblast activation protein (FAP). FAPI-74 can be used for FAP-positive tumor research .
    FAPI-74
  • HY-160607
    MMA-NODAGA

    		Radionuclide-Drug Conjugates (RDCs) Others
    MMA-NODAGA is a chelator for site-specific labeling of targeting proteins containing unpaired cysteine. MMA-NODAGA can be used to conjugate with exosome and 64Cu in image with positron emission tomography (PET) <[2].
    MMA-NODAGA
  • HY-146102
    M1 ligand 1

    		mAChR Others
    M1 ligand 1 (compound 3b-b) is a muscarinic acetylcholine receptor M1 ligand. M1 ligand 1 is a N-desmethyl congener of arecoline derivative. M1 ligand 1 can be used as PET (positron emission tomography) radiotracer .
    M1 ligand 1
  • HY-159001
    ZCDD083

    		Biochemical Assay Reagents Others
    ZCDD083 can be used as a positron emission tomography (PET) tracer for atherosclerotic plaques imagination, when labeled with 18F isotope .
    ZCDD083
  • HY-101184R
    T807 (Standard)

    AV-1451 (Standard)

    		 Reference Standards Tau Protein Neurological Disease
    T807 (Standard) is the analytical standard of T807. This product is intended for research and analytical applications. T807 a novel tau positron emission tomography (PET) tracer.
    T807 (Standard)
  • HY-173319
    FAP-IN-5

    		FAP Cancer
    FAP-IN-5 (Compound 4a) is an FAP inhibitor with an IC50 of 1.7 nM. FAP-IN-5 can be used in the research of tumor positron emission tomography (PET) imaging .
    FAP-IN-5
  • HY-129059
    Odapipam
    1 Publications Verification

    NNC 756

    		 Dopamine Receptor Neurological Disease
    Odapipam (NNC 756) is a selective, high affinity and benzazepine dopamine D1 receptor antagonist with a Kd of 0.18 nM. Odapipam is also a superior positron emission tomography (PET) radiotracer .
    Odapipam
  • HY-111514
    4-(6-Bromo-2-benzothiazolyl)benzenamine

    		Oxidative Phosphorylation Amyloid-β Neurological Disease
    4-(6-Bromo-2-benzothiazolyl)benzenamine is a β-amyloid PET (positron emission tomography) tracer that can be used in the diagnosis of neurological diseases, such as Alzheimer's and Down's syndrome.
    4-(6-Bromo-2-benzothiazolyl)benzenamine
  • HY-135497
    Fallypride

    		Dopamine Receptor Neurological Disease
    Fallypride is a potent antagonist of dopamine D2/D3 receptor. Fallypride, in the form of fallypride ( 18F), can be used as a positron emission tomography (PET) radiotracer .
    Fallypride
  • HY-158317
    SFB-AMD3465

    		CXCR Biochemical Assay Reagents Others
    SFB-AMD3465 is an AMD3465 (HY-15971A) derivative. SFB-AMD3465 is utilized as positron emission tomography (PET) tracer for CXCR4, when labeled with radioactive Fluorine .
    SFB-AMD3465
  • HY-103326
    NIDA-41020

    		Cannabinoid Receptor Neurological Disease
    NIDA-41020 is a potent and selective cannabinoid receptor 1(CB1) antagonist with a Ki of 4.1 nM. NIDA-41020 was designed as a potential radioligand for use in positron emission tomography (PET) .
    NIDA-41020
  • HY-101185
    T808

    		Tau Protein Neurological Disease
    T808 is a tau-selective Alzheimer’s PET ligand. T808 is a type of imaging agent used in positron emission tomography (PET) scans. It is a radiotracer that is used to help visualize certain areas of the body, such as the brain, in order to diagnose and monitor various medical conditions .
    T808
  • HY-167899
    PXT-012253

    		mGluR Neurological Disease
    PXT-012253 is a positron emission tomography (PET) ligand for mGluR4, as it binds to an allosteric site on mGluR4. PXT-012253 can be utilized in researches related to Parkinson's disease and levodopa-induced dyskinesia .
    PXT-012253
  • HY-D2334
    AlF-NOTA-c-d-VAP

    		Radionuclide-Drug Conjugates (RDCs) HSP Cancer
    AlF-NOTA-c-d-VAP is a peptide positron emission tomography (PET) probe that used for targeted tumor imaging of GRP78. AlF-NOTA-c-d-VAP demonstrates high stability in vitro and in vivo .
    AlF-NOTA-c-d-VAP
  • HY-100275
    MK-3328

    		Amyloid-β Neurological Disease
    MK-3328 is a β-Amyloid ligand, which exhibits high binding potency with an IC50 of 10.5 nM. MK-3328 is capable of being labelled with 18F for positron emission tomography (PET) imaging .
    MK-3328
  • HY-106244A
    DOTATATE acetate
    1 Publications Verification

    		 Radionuclide-Drug Conjugates (RDCs) Cancer
    DOTATATE acetate is a DOTA-conjugated peptide. DOTATATE acetate can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE (acetate) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTATATE acetate
  • HY-106244
    DOTATATE
    1 Publications Verification

    		 Radionuclide-Drug Conjugates (RDCs) Cancer
    DOTATATE is a DOTA-conjugated peptide. DOTATATE can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTATATE
  • HY-153549
    Pentixafor

    		Radionuclide-Drug Conjugates (RDCs) CXCR Others
    Pentixafor is a peptide that targets CXCR4. Pentixafor is capable of being labelled with 68Gallium ( 68Ga) for positron emission tomography (PET) imaging . Pentixafor can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    Pentixafor
  • HY-139048A
    Fluoroethylnormemantine hydrochloride

    		iGluR Neurological Disease
    Fluoroethylnormemantine hydrochloride, a derivative of Memantine, is an antagonist of the N-methyl-D-aspartate (NMDA) receptor. [ 18F]-Fluoroethylnormemantine hydrochloride can be used as a positron emission tomography (PET) tracer. Fluoroethylnormemantine hydrochloride exhibits anti-amnesic, neuroprotective, antidepressant-like and fear-attenuating effects .
    Fluoroethylnormemantine hydrochloride
  • HY-139048
    Fluoroethylnormemantine

    		iGluR Neurological Disease
    Fluoroethylnormemantine, a derivative of Memantine, is an antagonist of the N-methyl-D-aspartate (NMDA) receptor. [ 18F]-Fluoroethylnormemantine can be used as a positron emission tomography (PET) tracer. Fluoroethylnormemantine exhibits anti-amnesic, neuroprotective, antidepressant-like and fear-attenuating effects .
    Fluoroethylnormemantine
  • HY-101186
    MK-6240
    1 Publications Verification

    		 Tau Protein Neurological Disease
    MK-6240 is a blood-brain barrier-permeable positron emission tomography (PET) tracer targeting neurofibrillary tangles (NFTs) (Kd = 0.42 nM). MK-6240 can be used for imaging neurofibrillary tangle pathology in Alzheimer's disease and hereditary frontotemporal dementia .
    MK-6240
  • HY-158243
    Fallypride precursor

    		Dopamine Receptor Neurological Disease
    Fallypride precursor (Compound 15) can be used for synthesis of Fallypride (HY-135497). Fallypride is an antagonist of the dopamine D2/D3 receptor. Fallypride can be used as a positron emission tomography (PET) radiotracer when labeled with 18F .
    Fallypride precursor
  • HY-153248
    PBR28

    		Others Others
    PBR28 is an TSPO modulator, which can be used for prevention research of Pulmonary Arterial Hypertension (PAH). PBR28 can be used to trace 18 KDa transporter (TSPO) by adding radioactive labeling, which plays an important role in brain positron emission tomography (PET) imaging studies .
    PBR28
  • HY-137332
    N-Methylspiroperidol

    		Dopamine Receptor Neurological Disease
    N-Methylspiroperidol is a D2 receptor antagonist. N-Methylspiroperidol can be labeled as [18F]N-Methylspiroperidol and used in PET (Positron Emission Tomography) to study how it binds to the 5-HT2C receptor and the competition and effects of neurotransmitters like dopamine on these receptors .
    N-Methylspiroperidol
  • HY-126226
    MK-6240 Precursor

    		Drug Intermediate Neurological Disease
    MK-6240 Precursor (Compound 6e) is a crucial intermediate in the synthesis of [ 18F]-MK-6240 (Compound 6). [ 18F]-MK-6240 is a highly specific and selective positron emission tomography (PET) imaging agent used for the quantification of neurofibrillary tangles (NFTs) .
    MK-6240 Precursor
  • HY-173291
    Tau ligand-1

    		Tau Protein Neurological Disease
    Tau ligand-1 (Compound 75) is a ligand for aggregated tau protein that can penetrate the blood-brain barrier . In tissues from patients with Alzheimer's disease, progressive supranuclear palsy, corticobasal degeneration, and Pick's disease, Tau ligand-1 exhibits high affinity for aggregated tau protein, with equilibrium dissociation constant (KD) values ranging from 1 to 3.8 nM . Tau ligand-1 can serve as a potential positron emission tomography (PET) tracer and holds promise for application in positron emission tomography imaging studies of tau-related diseases in the central nervous system .
    Tau ligand-1
  • HY-159602
    BET BD2-IN-3

    		Epigenetic Reader Domain Cancer
    BET BD2-IN-3 (compound I-58) is an inhibitor of BET, targeting the BD2 domain of BET. BET BD2-IN-3 can be radiolabeled with [11C] for positron emission tomography (PET) imaging. BET [11C]BD2-IN-3 showed suitable biodistribution in peripheral organs and tissues in PET applications in mice .
    BET BD2-IN-3
  • HY-121810
    LBT-999

    		Dopamine Transporter Others
    LBT-999 is a phenyltropane derivative used for positron emission tomography (PET) exploration of the dopamine transporter (DAT). It has high affinity binding to DAT on rat striatal membranes and human postmortem brain slices in vitro, high uptake in the striatum in rat and baboon models in vivo, and its binding can be blocked by specific compounds.
    LBT-999
  • HY-120947
    AV-105

    		Drug Intermediate Neurological Disease
    AV-105 is a Florbetapir ( 18F)-radiolabeled slyrylpyridine tosylate precursor extracted from patent WO2010078370A1, example 1.5. AV-105 can synthesize 18F-radiolabeled compounds, which are used for positron emission tomography (PET) imaging of neurodegenerative diseases of the brain .
    AV-105
  • HY-152152
    JZP-MA-13

    		MAGL Neurological Disease
    JZP-MA-13 is a selective α/β-hydrolase domain 6 (ABHD6) inhibitor with an IC50 of 392 nM. JZP-MA-13 shows no inhibition of MAGL, ABHD12, FAAH, or other serine hydrolases. JZP-MA-13 is a positron emission tomography (PET) ligand for in vivo imaging of the ABHD6 .
    JZP-MA-13
  • HY-125399
    PSMA-11

    HBED-CC-PSMA

    		 PSMA Radionuclide-Drug Conjugates (RDCs) Cancer
    PSMA-11 is a small molecule ligand that targets prostate-specific membrane antigen (PSMA) and has the ability to inhibit PSMA activity. PSMA-11 can be used to synthesize 68Ga-PSMA-11, a positron emission tomography (PET) tracer that can be used to image advanced prostate cancer .
    PSMA-11
  • HY-117756
    Piflufolastat

    DCFPYL

    		 PSMA Others Cancer
    Piflufolastat (DCFPYL) can be used to the preparation of piflufolastat F 18 (DCFPyL F-18). piflufolastat F 18. Piflufolastat F-18 is an 18F-labelled diagnostic imaging agent. Piflufolastat F-18 can be used for positron emission tomography (PET) that targets prostate-specific membrane antigen (PSMA) .
    Piflufolastat
  • HY-111189
    GSK931145

    		GlyT Neurological Disease
    GSK931145 is a glycine transporter 1 (GlyT1) inhibitor with anti-epileptic activity. GSK931145 exhibits a low minimum effective dose in the maximum electrical stimulation threshold test, indicating that it has a significant anti-epileptic effect. GSK931145 is also suitable as a positron emission tomography (PET) radioligand for quantifying the availability of glycine transporters in the living brain .
    GSK931145
  • HY-141464
    Fmoc-L-Asn(beta-D-GlcNAc(Ac)3)-OH

    Fmoc-Asn(Ac3AcNH-beta-Glc)-OH

    		 Amino Acid Derivatives Cancer
    Fmoc-L-Asn(beta-D-GlcNAc(Ac)3)-OH (Fmoc-Asn(Ac3AcNH-beta-Glc)-OH) can be used in the synthesis of silicon-fluoride acceptor (SiFA) derivatized octreotate derivatives. SiFA-octreotate analogues, as tumor imaging agents, are useful tool for the research of positron emission tomography (PET) .
    Fmoc-L-Asn(beta-D-GlcNAc(Ac)3)-OH
  • HY-W422400
    Fluoroglutamine (2S,4R)

    		Biochemical Assay Reagents Others Cancer
    Fluoroglutamine (2S,4R) is a fluorinated derivative of glutamine. As a substrate for various aminotransferases, Fluoroglutamine (2S,4R) can be used as a tracer for positron emission tomography (PET) imaging. Fluoroglutamine (2S,4R) is applied in the research fields of tumor metabolism and imaging .
    Fluoroglutamine (2S,4R)
  • HY-W728451
    URB694

    		FAAH Cardiovascular Disease Neurological Disease
    URB694 is a carbamate FAAH inhibitor that irreversibly carbamoylate the nucleophile catalytic serine in FAAH active site. URB694 exhibits antidepressant-like activity and cardioprotective effects. URB694 can be used to prepare 11C-Carbonyl-URB694 for in vivo positron emission tomography (PET) imaging studies of the brain FAAH .
    URB694
  • HY-149766
    PB94

    		HDAC Neurological Disease
    PB94 is a selective HDAC11 inhibitor (IC50=108 nM). PB94 can be radiolabeled as [11C]-PB94 for use in positron emission tomography (PET), as well as brain uptake and metabolic properties in administered live animals. PB94 improves neuropathic pain in mice and could be used to study neurological indications .
    PB94
  • HY-163545
    Tc-Me2P

    		Drug Derivative Cancer
    Tc-Me2P is a 99MTC-labeled acrylamide (PnAO) derivative that contains two 4-methyl-2-nitroimidazole groups. The primary activity of Tc-Me2P is as an imaging agent for tumor hypoxia. By specifically binding to hypoxic regions in tumor tissue, it can be used for single photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging to detect hypoxia in tumors. Tc-Me2P can be used to study the targeting of different chemical structures in tumors and normal tissues .
    Tc-Me2P
  • HY-165425
    KR31173

    		Angiotensin Receptor Cardiovascular Disease
    KR31173 is an AT1 antagonist with an IC50 of 3.27  nM. KR31173 can be used as a positron emission tomography (PET) tracer after being labeled with 11C isotope. KR31173 shows promising biodistribution and pharmacological properties in mice. KR31173 selectively binds to organs known to contain a high density of AT1 angiotensin receptors in CD-1 mice .
    KR31173
  • HY-169071S
    ATX-1905

    		Phosphodiesterase (PDE) Others
    ATX-1905 is a positron emission tomography (PET) tracer that demonstrates good autotaxin (ATX) binding specificity and achieves semiquantification of lung ATX expression levels, which are elevated in fibrotic lungs. ATX-1905 exhibits elevated uptake in Bleomycin (HY-108345)-induced pulmonary fibrosis (BPF) lungs. ATX-1905 is promising for research of idiopathic pulmonary fibrosis (IPF) .
    ATX-1905
  • HY-75706
    N-Descyclopropanecarbaldehyde Olaparib

    		PARP Ligands for Target Protein for PROTAC Cancer
    N-Descyclopropanecarbaldehyde Olaparib is an analogue of Olaparib (HY-10162) containing DOTA moiety. N-Descyclopropanecarbaldehyde Olaparib is a PARP inhibitor used for synthesizing novel dual EGFR and PARP PROTAC, DP-C-4 (HY-141481) . N-Descyclopropanecarbaldehyde Olaparib can be radiolabeled with F-18 or fluorophore for positron emission tomography (PET) or optical imaging in several types of tumor .
    N-Descyclopropanecarbaldehyde Olaparib
  • HY-P10744
    BQ7859

    		Radionuclide-Drug Conjugates (RDCs) PSMA Cancer
    BQ7859 is a probe targeting PSMA that contains a NOTA chelator and demonstrates excellent imaging performance. BQ7859 can be labeled with various radionuclides, such as 68Ga, 18F, 55Co, and 111In. In a mouse prostate cancer xenograft model, BQ7859 (labeled with 111In) efficiently accumulates in tumor regions in a PSMA-dependent manner and provides high-contrast tumor imaging. BQ7859 shows potential for research in prostate cancer imaging, particularly in positron emission tomography (PET) and single-photon emission computed tomography (SPECT) . BQ7859 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    BQ7859
  • HY-162574
    CYP11B2-IN-2

    		Cytochrome P450 Cancer
    CYP11B2-IN-2 (Compound 10k) is an inhibitor for enzyme aldosterone synthase CYP11B2 with an IC50 of 0.3 nM. CYP11B2-IN-2 CYP11B-IN-2 is labeled with 18F and can be used as a positron emission tomography (PET) tracer for the diagnosis of primary aldosteronism .
    CYP11B2-IN-2
  • HY-P5413
    [Lys3]-Bombesin

    		Cholecystokinin Receptor Others
    [Lys3]-Bombesin is a biological active peptide. (PET (Positron Emission Tomography) imaging of [Lys3]-bombesin is able to detect gastrin-releasing peptide receptor (GRPR) positive prostate cancer. An immunoconjugate of [Lys3]-bombesin and corresponding monoclonal antibody can specifically induce (CD64)-dependent monocyte and neutrophil-mediated lysis of small cell carcinoma.)
    [Lys3]-Bombesin
  • HY-119190
    PF-06445974

    		Phosphodiesterase (PDE) Neurological Disease
    PF-06445974, a promising positron emission tomography (PET) lead, has exquisite potency at PDE4B with an IC50 <1 nM. The IC50 values are 36, 4.7 and 17 nM for PDE4D, PDE4A and PDE4C, respectively. PF-06445974 has good selectivity over PDE4D, excellent brain permeability, and a high level of specific binding in the "cold tracer" study .
    PF-06445974
  • HY-167898
    MeS-IMPY

    		Amyloid-β Neurological Disease
    MeS-IMPY is a ligand of β-amyloid plaques. MeS-IMPY shows a high binding affinity to β-amyloid plaques extracted from Alzheimer's disease (AD) human brains or AD brain homogenates compared to IMPY (Ki=7.93 and 8.95 nM, respectively). [ 11C]MeS-IMPY is a potential radioligand for imaging β-amyloid plaques with positron emission tomography (PET) .
    MeS-IMPY

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: